Adult Dosing Recommendations in Hepatic Impairment
- Brown N, Ho DHW, Fong KL, et al. Effects of hepatic function on vancomycin clinical pharmacology. Antimicrob Agents Chemother 1983;23:603-9.
- Drug Evaluation monographs, Micromedex online 1999.
- Efthymiopoulos C, Bramer SL, Maroli A, et al. Grepafloxacin pharmacokinetics in individuals with hepatic dysfunction. Clin Pharmacokinet 1997;33:25-31.
- Evans WE, Schentag JJ, Jusko WJ, eds. Applied pharmacokinetics. Principles of therapeutic drug monitoring. Vancouver, WA: Applied Therapeutics Inc.; 3rd ed. 1992.
- Hall KW, Nightingale CH, Gibaldi M, et al. Pharmacokinetics of erythromycin in normal and alcoholic liver disease subjects. J Clin Pharmacol 1982;22:321-5.
- Hinthorn DR, Baker LH, Romig DA, et al. Use of clindamycin in patients with liver disease. Antimicrob Agents Chemother 1976;9:498-501.
- Tschida SJ, Vance-Bryan K, Zaske DE. Anti-infective agents and hepatic disease. Med Clin North Am 1995;79:895-917.
- Kenyon J (ed). Tailor antibacterial dosages in hepatic impairment. Drugs Ther Perspect 1993;I:12-13.
- Kubisty CA, Arns PA, Wedlund PJ, et al. Pharmacotherapy in liver failure. In: Chernow B. Pocket Book of Critical Care Pharmacotherapy. Baltimore; Williams & Wilkins; 1995.
- Lietman PS. Liver disease, aminoglycoside antibiotics and renal dysfunction (editorial). Hepatology 1988;8:966-8.
- Matzke GR, Kovarik JM. Clinical pharmacokinetics of anti-infectives. In: Koda-Kimble MA, Young LY, eds. Applied therapeutics: the clinical use of drugs. 5th ed. Vancouver, WA: Applied Therapeutics Inc. 1992;34:34-8.
- McCormick PA, Greenslade L, Kibbler CC, et al. Further evidence against the use of aminoglycosides in cirrhotic patients (letter). Gastroenterology 1998;114:612-3.
- Meyer JM, Rodvold KA. Clinical pharmacology of antimicrobial agents in cirrhosis. Infect Med 1997;14:541-7.
- Moore, RD, Smith CR, Lipsky JJ, et al. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Int Med 1984;100:352-7.
- Product monographs. Compendium of Pharmaceuticals and Specialties. 40th ed. Toronto: Webcom Limited; 2005.
- Westphal JF, Brogard JM. Clinical pharmacokinetics of newer antibacterial agents in liver disease. Clin Pharmacokinet 1993;24:46-58.
- Westphal JF, Jehl F, Vetter D. Pharmacological, toxicologic, and microbiological considerations in the choice of initial antibiotic therapy for serious infections in patients with cirrhosis of the liver. Clin Infect Dis 1994;18:324-35.
- Williams RL, Mamelok RD. Hepatic disease and drug pharmacokinetics. Clin Pharmacokinet 1980;5:528-47.